Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104873 | 0.93 | GSK3B (0.64) | GSK3B | |
| SCHEMBL5098749 | 0.92 | GSK3B (0.62) | GSK3B | |
| SCHEMBL5092204 | 0.88 | GSK3B (0.69) | GSK3B | |
| SCHEMBL2403039 | 0.87 | GSK3B (0.67) | GSK3B | |
| SCHEMBL5098699 | 0.86 | GSK3B (0.66) | GSK3B | |
| SCHEMBL5047824 | 0.86 | GSK3B (0.66) | GSK3B | |
| SCHEMBL5104842 | 0.86 | GSK3B (0.66) | GSK3B | |
| SCHEMBL5092132 | 0.86 | GSK3B (0.66) | GSK3B | |
| SCHEMBL5098168 | 0.86 | GSK3B (0.66) | GSK3B | |
| SCHEMBL5092186 | 0.84 | GSK3B (0.61) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | claimed |
| EP-1276738-B1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-12 | — | — | EP | claimed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | claimed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | claimed |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | SANOFI (FR) | 2003-10-02 | — | — | US | claimed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1276738-B8 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-20 | — | — | EP | disclosed |
| EP-1276738-B1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-12 | — | — | EP | disclosed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | disclosed |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | SANOFI (FR) | 2003-10-02 | — | — | US | disclosed |
| EP-1276738-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | Sanofi-Aventis (FR) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001070729-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI-SYNTHELABO (FR) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | GSK3A, GSK3B, PSEN2 | GSK3B 2/4885 |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | GSK3A, GSK3B, CSNK2A3 | GSK3B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.